Key facts
- It has raised $17.6M; the latest was Seed Round ($17.6M) in Jan 2026.
- Notable investors include European Commission, Brabantse Ontwikkelings Maatschappij, Invest-NL (Investment Company), Government of the Netherlands, Borski Fund — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for ShanX Medtech
- ·The full record, as it builds
Funding rounds
No funding rounds for ShanX Medtech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ShanX Medtech
Developer of a diagnostic platform designed to accelerate antibiotic susceptibility testing and improve infection management. The company's platform develops rapid Antibiotic Susceptibility Testing (AST) systems that integrate real-time analysis, portability and broad-spectrum pathogen profiling, enabling healthcare providers to identify effective treatments more fast and reduce patient risk, hospital stays and antimicrobial resistance.
- Sector
- Healthcare
- HQ
- Eindhoven, Netherlands
- Founded
- 2019
- Employees
- 11
- Website
- shanxmedtech.com/
- Ownership
- Privately Held (backing)
ShanX Medtech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ShanX Medtech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ShanX Medtech in its N-PORT filings yet. We sweep new filings monthly.